-
J335104-10mgJP 1302 dihydrochloride is a potent and selective α2C-AR adrenoreceptor antagonist. JP 1302 dihydrochloride strongly antagonizes adrenaline-stimulated 35GTPγS binding|in vitro|.
-
J335104-50mgJP 1302 dihydrochloride is a potent and selective α2C-AR adrenoreceptor antagonist. JP 1302 dihydrochloride strongly antagonizes adrenaline-stimulated 35GTPγS binding|in vitro|.
-
J414105-100mgInformationJPH203 JPH203 (KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral
-
J414105-10mgInformationJPH203 JPH203 (KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral
-
J414105-25mgInformationJPH203 JPH203 (KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral
-
J414105-50mgInformationJPH203 JPH203 (KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral
-
J414105-5mgInformationJPH203 JPH203 (KYT-0353, JPH-203SBECD), a selective L-type amino acid transporter 1 inhibitor, shows a dramatic inhibition of leucine uptake (IC50=0.06 µM) and cell growth (IC50=4.1 µM) in human colon cancer cells (HT-29), human oral
-
J288565-100mgPotent and selective SAM-competitive EZH2 inhibitor.
-
J288565-10mgPotent and selective SAM-competitive EZH2 inhibitor.
-
J288565-25mgPotent and selective SAM-competitive EZH2 inhibitor.
-
J288565-50mgPotent and selective SAM-competitive EZH2 inhibitor.
-
J288565-5mgPotent and selective SAM-competitive EZH2 inhibitor.